In late January, Cynata received regulatory approval for commencement of its phase 2 clinical trial in acute graft-versus-host disease (aGVHD). It mostly affects women, and nothing has yet been established as an optimal second line therapy for either acute or chronic GvHD.
However, mesenchymal stromal cells (MSCs), those which Cynata manufactures, have shown substantial promise. Read the news here: